Literature DB >> 7512880

Production of multiple cytokines by cultured human melanomas.

J L Bennicelli1, D Guerry.   

Abstract

We screened a panel of 8 primary and 21 metastatic melanoma cell lines for constitutive secretion of cytokines. Melanomas expressed bioactivity for TGF-beta (8/25 lines) and IFN (7/12), but not IL-2. Immunoassays detected IL-1 alpha (4/25), IL-1 beta (12/25), IL-6 (13/29), IL-8 (29/29), TGF-beta 2 (5/12) and GM-CSF (11/29), but not IL-3, IL-4, TNF-alpha, or IFN-gamma. There was no preferential association of cytokine production with cells cultured from primary versus metastatic disease, and only IL-8 was produced by all lines tested. These data demonstrate that cultured melanomas produce a variety of cytokines which are potentially capable of influencing tumor growth in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512880     DOI: 10.1111/j.1600-0625.1993.tb00031.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  13 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

2.  Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Authors:  Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

3.  GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation.

Authors:  Colleen S Curran; Michael D Evans; Paul J Bertics
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

4.  Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.

Authors:  Regina Lin; Ling Chen; Gang Chen; Chunyan Hu; Shan Jiang; Jose Sevilla; Ying Wan; John H Sampson; Bo Zhu; Qi-Jing Li
Journal:  J Clin Invest       Date:  2014-10-27       Impact factor: 14.808

5.  TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

6.  Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  Int Immunol       Date:  2011-10-24       Impact factor: 4.823

7.  CD200 is induced by ERK and is a potential therapeutic target in melanoma.

Authors:  Kimberly B Petermann; Gabriela I Rozenberg; Daniel Zedek; Pamela Groben; Karen McKinnon; Christin Buehler; William Y Kim; Janiel M Shields; Shannon Penland; James E Bear; Nancy E Thomas; Jonathan S Serody; Norman E Sharpless
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

8.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

9.  An Improved In Vivo Methodology to Visualise Tumour Induced Changes in Vasculature Using the Chick Chorionic Allantoic Membrane Assay.

Authors:  Naside Mangir; Ahtasham Raza; John W Haycock; Christopher Chapple; Sheila Macneil
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

Review 10.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.